Tiziana Life Sciences (TLSA) announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer’s disease who was treated for three months with intranasal foralumab under an expanded access program. The microglial TSPO PET scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with Alzheimer’s disease progression.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences announces results from study of nasal foralumab
- Tiziana Life Sciences Reports Positive Results from Nasal Foralumab Study in MS
- Tiziana Life Sciences Delays Annual Report Filing
- Tiziana Life Sciences Expands Phase 2 Trial for Intranasal Foralumab with UMass Dosing
- Tiziana Life Sciences announces UMass commences Phase 2 na-SPMS trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue